Stockscreener 앱 받기
2.10
4.55%
-0.10
전일 마감가:
$2.20
열려 있는:
$2.14
하루 거래량:
109.32K
Relative Volume:
0.69
시가총액:
$62.50M
수익:
-
순이익/손실:
$-13.08M
주가수익비율:
-4.7554
EPS:
-0.4416
순현금흐름:
-
1주 성능:
-16.00%
1개월 성능:
-17.32%
6개월 성능:
-50.47%
1년 성능:
-66.67%
1일 변동 폭
$2.035
$2.14
1주일 범위
$1.98
$2.60
52주 변동 폭
$1.98
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.10 | 74.41M | 0 | -13.08M | 0 | -0.4416 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Telomir Pharmaceuticals secures $3M in straight equity sale - MSN
Telomir Pharmaceuticals secures $3 million investment By Investing.com - Investing.com Canada
Telomir Pharmaceuticals appoints new CFO By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals appoints new CFO - Investing.com
Telomir Pharmaceuticals raises $3 million in equity By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale - marketscreener.com
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - Corsicana Daily Sun
Insider Confidence: Telomir Secures $3M Premium Investment for Breakthrough Rare Disease Drug Program - Stock Titan
Telomir Pharmaceuticals raises $3 million in equity - Investing.com
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND - Benzinga
TELO stock touches 52-week low at $2.26 amid market challenges - Investing.com Nigeria
Telomir Pharmaceuticals - The Pharma Letter
Telomir Pharma touts breakthrough in drug-resistant infections - The Pharma Letter
Telomir unveils new drug candidate against resistant bacteria By Investing.com - Investing.com South Africa
Telomir unveils new drug candidate against resistant bacteria - Investing.com Australia
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity - Jonesboro Sun
First-Ever Stable Silver(II) Drug Defeats Antibiotic-Resistant Superbugs in Groundbreaking Study - Stock Titan
Barclays PLC Raises Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Shares Bought by Wells Fargo & Company MN - Defense World
Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Monday - Defense World
Telomir-1 shows promise in preclinical cellular aging study By Investing.com - Investing.com South Africa
Telomir-1 shows promise in preclinical cellular aging study - Investing.com Australia
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia - Weatherford Democrat
JPMorgan Chase & Co. Acquires 37,980 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Geode Capital Management LLC Has $1.71 Million Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $2.35 amid market challenges - Investing.com
TELO stock touches 52-week low at $2.46 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.46 amid market challenges - Investing.com
Corebridge Financial Inc. Has $40,000 Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Comparing Telomir Pharmaceuticals (TELO) and The Competition - Defense World
TELO stock touches 52-week low at $2.59 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.59 amid market challenges - Investing.com
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - ACCESS Newswire
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses - ACCESS Newswire
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):